JP2017535756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535756A5 JP2017535756A5 JP2017516994A JP2017516994A JP2017535756A5 JP 2017535756 A5 JP2017535756 A5 JP 2017535756A5 JP 2017516994 A JP2017516994 A JP 2017516994A JP 2017516994 A JP2017516994 A JP 2017516994A JP 2017535756 A5 JP2017535756 A5 JP 2017535756A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- small molecule
- acid
- compared
- control sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20145855 | 2014-10-02 | ||
| FI20145855 | 2014-10-02 | ||
| PCT/FI2015/050654 WO2016051020A1 (en) | 2014-10-02 | 2015-10-02 | Methods for detecting ovarian cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535756A JP2017535756A (ja) | 2017-11-30 |
| JP2017535756A5 true JP2017535756A5 (https=) | 2018-11-29 |
| JP6892820B2 JP6892820B2 (ja) | 2021-06-23 |
Family
ID=55629471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516994A Active JP6892820B2 (ja) | 2014-10-02 | 2015-10-02 | 卵巣癌を検出する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10534001B2 (https=) |
| EP (1) | EP3201623B1 (https=) |
| JP (1) | JP6892820B2 (https=) |
| KR (1) | KR20170061704A (https=) |
| CN (1) | CN106716127B (https=) |
| AU (1) | AU2015326756A1 (https=) |
| BR (1) | BR112017006593A2 (https=) |
| CA (1) | CA2959832A1 (https=) |
| SG (1) | SG11201701875YA (https=) |
| WO (1) | WO2016051020A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3351938A1 (en) * | 2017-01-18 | 2018-07-25 | BIOCRATES Life Sciences AG | New biomarkers for assessing ovarian cancer |
| US20210405054A1 (en) | 2017-07-05 | 2021-12-30 | Zora Biosciences Oy | Methods for detecting ovarian cancer |
| CN107656006A (zh) * | 2017-09-08 | 2018-02-02 | 上海市东方医院 | 用于检测血清或者血浆中α‑羟基丁酸浓度的试剂盒和方法 |
| CN108152430A (zh) * | 2017-12-21 | 2018-06-12 | 上海中科新生命生物科技有限公司 | 基于prm检测的卵巢癌标志物检测试剂盒及检测方法 |
| WO2020160108A1 (en) * | 2019-01-30 | 2020-08-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Lipid biomarkers for cancer screening and monitoring |
| CN111430030A (zh) * | 2020-04-17 | 2020-07-17 | 武汉大学 | 生物标志物在卵巢癌评估中的应用方法及系统 |
| CN114544848B (zh) * | 2020-11-25 | 2023-04-28 | 中国科学院大连化学物理研究所 | 一种用于诊断卵巢上皮癌的血清脂质标志物组合物及试剂盒和其与应用 |
| EP4246146A1 (en) * | 2022-03-14 | 2023-09-20 | Fundació Institut Mar d'Investigacions Mèdiques (IMIM) | Method for diagnosing cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824555A (en) * | 1996-05-30 | 1998-10-20 | The Cleveland Clinic Foundation | Method of detecting gynecological carcinomas |
| US20050054942A1 (en) * | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
| US20030180953A1 (en) * | 2000-12-29 | 2003-09-25 | Elitra Pharmaceuticals, Inc. | Gene disruption methodologies for drug target discovery |
| WO2003015436A1 (de) * | 2001-08-10 | 2003-02-20 | Siemens Aktiengesellschaft | Verfahren zum schnellen und lokalen fehlerbeheben beim ausfall einzelner physikalischer verbindungen in gebündelten kommunikationsverbindungen und kommunikationssystem-vorrichtung zum durchführen des verfahrens |
| US20040180387A1 (en) * | 2003-03-13 | 2004-09-16 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer |
| US20050170441A1 (en) | 2003-09-12 | 2005-08-04 | Health Research, Inc. | Early detection of cancer of specific type using 1HNMR metabonomics |
| WO2009052186A1 (en) * | 2007-10-15 | 2009-04-23 | Georgia Tech Research Corporation | Metabolomics-based identification of disease-causing agents |
| WO2009096903A1 (en) | 2008-01-28 | 2009-08-06 | National University Of Singapore | Lipid tumour profile |
| US20120004854A1 (en) | 2008-05-28 | 2012-01-05 | Georgia Tech Research Corporation | Metabolic biomarkers for ovarian cancer and methods of use thereof |
| JP4744618B2 (ja) * | 2009-04-13 | 2011-08-10 | シャープ株式会社 | ガス成分検出装置 |
| BRPI1016102A2 (pt) * | 2009-04-15 | 2015-09-01 | Sanford Burhnham Medical Res Inst | Inibidores de proteínas anti-apoptótica baseados em naftaleno |
| US20120197539A1 (en) * | 2009-10-09 | 2012-08-02 | Carolyn Slupsky | Methods for diagnosis, treatment and monitoring of patient health using metabolomics |
| US20110114511A1 (en) * | 2009-11-17 | 2011-05-19 | Sjong Angele | Apparatus for detecting volatile organic compounds and related methods |
| GB201016139D0 (en) | 2010-09-24 | 2010-11-10 | Univ Leuven Kath | Cancer phosholipidome |
| FI20115576A0 (fi) * | 2011-06-10 | 2011-06-10 | Teknologian Tutkimuskeskus Vtt Oy | Menetelmä Alzheimerin taudin diagnoimiseksi |
| WO2013016700A1 (en) * | 2011-07-27 | 2013-01-31 | The Research Foundation Of State University Of New York | Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc |
-
2015
- 2015-10-02 KR KR1020177011691A patent/KR20170061704A/ko not_active Withdrawn
- 2015-10-02 WO PCT/FI2015/050654 patent/WO2016051020A1/en not_active Ceased
- 2015-10-02 EP EP15846140.0A patent/EP3201623B1/en active Active
- 2015-10-02 CA CA2959832A patent/CA2959832A1/en not_active Abandoned
- 2015-10-02 JP JP2017516994A patent/JP6892820B2/ja active Active
- 2015-10-02 US US15/513,755 patent/US10534001B2/en active Active
- 2015-10-02 SG SG11201701875YA patent/SG11201701875YA/en unknown
- 2015-10-02 BR BR112017006593A patent/BR112017006593A2/pt not_active Application Discontinuation
- 2015-10-02 CN CN201580052938.0A patent/CN106716127B/zh active Active
- 2015-10-02 AU AU2015326756A patent/AU2015326756A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535756A5 (https=) | ||
| Zheng et al. | A novel urinary metabolite signature for diagnosing major depressive disorder | |
| AU2017201020B2 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
| Jung et al. | Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolomic profiling | |
| Liu et al. | LC-MS-based plasma metabolomics and lipidomics analyses for differential diagnosis of bladder cancer and renal cell carcinoma | |
| Wang et al. | The early diagnosis and monitoring of squamous cell carcinoma via saliva metabolomics | |
| Baranyi et al. | Nitric oxide-related biological pathways in patients with major depression | |
| AU2012343843B2 (en) | Device and methods to diagnose pancreatic cancer | |
| Tumas et al. | Metabolomics in pancreatic cancer biomarkers research | |
| EP3084443B1 (en) | Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel | |
| Li et al. | Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study | |
| Liesenfeld et al. | Changes in urinary metabolic profiles of colorectal cancer patients enrolled in a prospective cohort study (ColoCare) | |
| JP7094700B2 (ja) | 喀痰試料中のバイオマーカーとしての細胞外遊離ヌクレオソームの使用 | |
| AU2010326737A1 (en) | Means and methods for diagnosing multiple sclerosis | |
| Takanashi et al. | Sphingomyelin (d35: 1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study | |
| Zhang et al. | High Sam68 expression predicts poor prognosis in non-small cell lung cancer | |
| Velenosi et al. | Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer | |
| EP2904397B1 (en) | Means and methods for diagnosing recurrence of prostate cancer after prostatectomy | |
| Meng et al. | Identification of CALM as the potential serum biomarker for predicting the recurrence of nasopharyngeal carcinoma using a mass spectrometry-based comparative proteomic approach | |
| Chen et al. | Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability | |
| Zhao et al. | Screening and identification of apolipoprotein AI as a potential hepatoblastoma biomarker in children, excluding inflammatory factors | |
| Kumar et al. | Metabolomics of prostate cancer: Knock-in versus knock-out prostate | |
| WO2025068237A1 (en) | Ex vivo method for predicting the response to an immunotherapy treatment of hepatocellular carcinoma in a subject | |
| ES2717458T3 (es) | Dispositivo y procedimientos para diagnosticar cáncer de páncreas | |
| HK1255151B (en) | Use of cell-free nucleosomes as biomarkers in sputum samples |